5:35 PM
 | 
Oct 19, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

CHMP recommends Roche's Alecensa for first-line NSCLC

EMA's CHMP recommended approval of Alecensa alectinib (AF802, CH5424802, RG7853, RO5424802) from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) as monotherapy for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive, advanced non-small...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >